IHL-42X screening begins as Incannex Healthcare enters a faster-moving oral sleep apnea race

Incannex Healthcare Inc. (Nasdaq: IXHL) has begun screening potential participants in the DReAMzz Phase 2 study of IHL-42X, moving its lead obstructive sleep apnea program from operational preparation into active recruitment. The study will compare nine dose combinations of dronabinol and acetazolamide to determine which formulation should advance into a planned Phase 3 registration program. The milestone matters because choosing the wrong dose could expose Incannex Healthcare to avoidable efficacy, safety and financing risks during a considerably more expensive pivotal trial. However, screening is not the same as enrolling or dosing participants, and the company disclosed no new clinical results on July 23, 2026. Incannex Healthcare shares were trading near $3.17, up approximately 1.4%, giving the company a market capitalization of about $39 million despite reporting $74.5 million in cash at March 31.

Why DReAMzz participant screening is strategically important but not yet a major valuation catalyst

The first approved DReAMzz sites are now screening adults with obstructive sleep apnea who are unable or unwilling to use positive airway pressure therapy consistently. Incannex Healthcare plans to recruit approximately 120 participants across 14 United States sites for three randomized, double-blind crossover studies. Each crossover will compare three IHL-42X dose combinations with placebo, creating nine active formulations built around different ratios of dronabinol and acetazolamide.

The trial is designed to determine whether dose optimization can produce a more consistent and commercially attractive response than the doses evaluated in the earlier RePOSA study. Incannex Healthcare could have attempted to move directly into Phase 3 following its positive Phase 2 results, but management elected to add DReAMzz after reviewing the data and discussing the development pathway with the United States Food and Drug Administration. The company believes that spending more time refining the formulation now can reduce the probability of a costly Phase 3 failure later.

That decision is financially defensible because pivotal sleep studies involving hundreds of patients, multiple countries, manufacturing scale-up and long treatment periods can consume substantially more capital than a 120-patient dose-confirmation trial. A formulation that generates strong responses in selected patients but inconsistent average efficacy could struggle during Phase 3. A formulation that improves breathing events but creates excessive adverse effects from dronabinol or acetazolamide could face discontinuations, regulatory concerns and weak commercial adoption.

The earlier RePOSA trial produced statistically significant improvements in apnea-hypopnea index and oxygen-desaturation measures compared with placebo. However, the widely promoted reduction of up to 83% represented the maximum response observed in an individual high-dose participant rather than the average effect across the treatment group. Approximately 41.2% of high-dose patients and 33.3% of low-dose patients achieved reductions in apnea-hypopnea index exceeding 30%, while 14.7% and 13.9%, respectively, achieved reductions above 50%.

Those responder rates help explain why Incannex Healthcare wants to test additional ratios. The business opportunity will depend less on the most dramatic individual result and more on whether the company can produce a predictable benefit across a broad patient population. Commercial insurers, regulators and sleep specialists will evaluate average efficacy, responder consistency, long-term safety, patient-reported improvement and treatment persistence rather than a single maximum reduction.

DReAMzz will also use two baseline polysomnography assessments and exclude participants showing excessive night-to-night variability. Incannex Healthcare added this measure after identifying intra-patient variability as an issue in earlier development. The protocol will collect more baseline information, monitor study-drug administration more closely and simplify certain patient-reported questionnaires, indicating that the company is using DReAMzz to correct operational weaknesses as well as optimize dosing.

How Incannex Healthcare’s cash balance, warrants and share buybacks shape the IHL-42X investment case

Incannex Healthcare reported $74.5 million in cash and cash equivalents at March 31, 2026, compared with $15 million at June 30, 2025. Current assets exceeded current liabilities by approximately $78.2 million, and management said its available resources were sufficient to fund planned operations for at least 12 months from the issuance of the quarterly financial statements.

The company’s July 23 market capitalization of approximately $39 million was considerably below the March cash balance. That apparent discount is one reason Incannex Healthcare has argued that the market is assigning limited value to IHL-42X, its PSX-001 anxiety program and the rest of its pipeline. The comparison should nevertheless be treated cautiously because the March cash figure is historical, clinical spending has continued and Incannex Healthcare used another $6.8 million to repurchase shares between April 1 and May 15.

Incannex Healthcare raised $10 million in March through the sale of approximately two million shares or share equivalents at a combined price of $5 each. Investors also received warrants to purchase another two million shares at $6.50 through March 2031. Full cash exercise of those warrants could provide an additional $13 million, but it would also increase the outstanding share count.

Management said the March financing was expected to fund DReAMzz, allowing the existing cash balance to remain available for Phase 3 development, which it anticipated beginning in the second half of 2027. That separation creates a relatively clear financing narrative: the registered direct offering finances dose optimization, while the earlier capital raises preserve resources for pivotal development. The timeline and spending assumptions remain subject to recruitment rates, trial results, regulatory feedback and the final Phase 3 design.

The company also completed a one-for-30 reverse stock split in February 2026 after its pre-split share count had expanded to approximately 358.3 million. The transaction reduced the number of outstanding shares to roughly 11.9 million and allowed the stock to trade at a higher nominal price, but it did not change Incannex Healthcare’s underlying enterprise value. Historical share prices and per-share comparisons must therefore be adjusted before drawing conclusions about long-term stock performance.

Incannex Healthcare has simultaneously been issuing and repurchasing shares. By May 15, the company had repurchased approximately 2.1 million post-split shares for about $9.1 million under a $20 million authorization. Buying stock below reported cash value can increase the ownership percentage of remaining investors and signal management confidence, but using clinical-stage biotechnology capital for repurchases also creates an opportunity cost when Phase 3 spending lies ahead.

This capital allocation strategy is unusual enough to deserve scrutiny. Incannex Healthcare raised $10 million in March while spending $6.8 million on buybacks during the following six weeks. The transactions were not necessarily funded from the same pool, and management has said the offering proceeds are allocated toward DReAMzz, but the combination illustrates the tension between correcting an undervalued share price and preserving maximum liquidity for drug development.

The company used $16.2 million in operating cash during the nine months ended March 31, up from $11 million a year earlier. Research and development expenses temporarily declined following completion of earlier IHL-42X studies, but Incannex Healthcare has warned that development spending should rise substantially as DReAMzz and future late-stage programs progress.

Why Apnimed’s AD109 filing and Eli Lilly’s Zepbound approval raise the competitive bar for IHL-42X

The competitive landscape has advanced considerably while Incannex Healthcare has been refining IHL-42X. Apnimed has completed two Phase 3 trials of AD109, an investigational oral therapy targeting upper-airway neuromuscular dysfunction, and submitted a New Drug Application to the United States Food and Drug Administration. Apnimed expects a potential regulatory action date in the first quarter of 2027 if the agency accepts the application for review.

That timeline creates a meaningful first-mover challenge. Incannex Healthcare is screening patients in a Phase 2 dose-confirmation study while a competing oral therapy has already completed Phase 3 and entered the application process. Even if IHL-42X ultimately produces compelling results, AD109 could establish physician familiarity, reimbursement pathways and commercial relationships before Incannex Healthcare reaches the market.

The two therapies use different mechanisms and may eventually serve different patient segments. IHL-42X combines dronabinol, which is intended to influence upper-airway and respiratory control, with acetazolamide, which alters carbon-dioxide responsiveness and respiratory drive. AD109 combines atomoxetine and aroxybutynin to increase upper-airway muscle activity and reduce airway collapse during sleep.

Incannex Healthcare may still differentiate IHL-42X through efficacy, once-daily dosing, patient-reported benefits or performance in particular biological subgroups. However, it can no longer build its investment case around the general scarcity of oral obstructive sleep apnea medicines. The more relevant comparison is whether IHL-42X can deliver sufficient efficacy and tolerability to compete against an oral product that may already be approved by the time Incannex Healthcare begins Phase 3.

Eli Lilly and Company has also changed the pharmaceutical treatment landscape with Zepbound, or tirzepatide. The United States Food and Drug Administration approved Zepbound in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, making it the first medication approved specifically for the condition. The approval is limited to adults with obesity and requires use alongside reduced-calorie nutrition and increased physical activity.

IHL-42X could potentially address a broader group that includes patients without obesity and people unable to tolerate positive airway pressure devices. That distinction may preserve a substantial market opportunity even as weight-loss medicines expand. Incannex Healthcare must still demonstrate that the product can deliver clinically meaningful breathing and functional improvements without requiring weight loss as the primary mechanism.

The presence of Zepbound and the progress of AD109 raise the commercial standard. A future IHL-42X filing will be assessed in a market where physicians may already have a weight-loss-based pharmaceutical option for obese patients and a dedicated oral neuromuscular therapy for a broader population. Incannex Healthcare’s combination will need to demonstrate why another oral therapy is necessary and which patients are most likely to benefit.

What Incannex Healthcare must prove before IHL-42X can justify a Phase 3 valuation premium

The July 23 screening announcement confirms that DReAMzz is operational, but the market is likely to reserve a meaningful valuation premium until Incannex Healthcare reports actual enrollment, dosing and efficacy progress. The immediate milestones include first-patient dosing, recruitment across all planned sites, completion of the crossover periods and identification of a preferred formulation.

Recruitment may be complicated by the study design. Participants will undergo multiple 28-day treatment periods, placebo exposure, sleep-laboratory assessments and controlled-substance procedures related to dronabinol. Crossover designs can generate efficient within-patient comparisons, but they also require substantial participant commitment and careful management of treatment sequencing.

Safety will be as important as apnea-hypopnea index improvement. Dronabinol can create psychoactive, cognitive and psychiatric effects, while acetazolamide can cause electrolyte changes, tingling, fatigue and other adverse reactions. The selected dose must be suitable for nightly chronic use rather than only short-term administration under trial supervision.

Incannex Healthcare also needs clarity on the eventual regulatory route. The company has suggested that IHL-42X could use the 505(b)(2) pathway because dronabinol and acetazolamide are established active ingredients. That pathway may allow reliance on selected existing data, but it does not remove the need to prove that the fixed-dose combination is safe, effective and appropriately manufactured for obstructive sleep apnea.

The current share price reflects both skepticism and potential optionality. Incannex Healthcare trades below its last reported cash balance, has no approved products and faces a competitor already pursuing United States approval. DReAMzz can narrow that valuation gap by producing a clearly differentiated dose and a credible Phase 3 plan, but participant screening alone does not answer the questions keeping the enterprise value depressed.

The central investment issue is no longer whether an oral sleep apnea therapy could attract demand. Eli Lilly and Company and Apnimed have already validated pharmaceutical interest in the category. Incannex Healthcare must now show that IHL-42X can arrive with enough differentiation to claim a commercially meaningful position rather than becoming a later entrant in an increasingly sophisticated market.

Key takeaways from Incannex Healthcare’s DReAMzz screening and IHL-42X investment outlook

• Incannex Healthcare has started screening potential participants in the 120-patient DReAMzz Phase 2 study, but the company has not yet announced first-patient enrollment, dosing or new efficacy data.
• DReAMzz will compare nine dronabinol and acetazolamide combinations, making dose selection the immediate value driver before Incannex Healthcare commits capital to a larger Phase 3 program.
• The earlier 83% apnea-hypopnea index reduction represented the strongest individual response, not the average RePOSA outcome, increasing the importance of producing more consistent responder rates.
• Incannex Healthcare reported $74.5 million in cash at March 31 against a July 23 market capitalization near $39 million, although ongoing operating expenses and post-quarter share repurchases reduce the usefulness of a simple cash-to-market-value comparison.
• The company raised $10 million at $5 per share in March and issued warrants exercisable at $6.50, providing potential additional capital but creating future dilution if exercised.
• Incannex Healthcare repurchased approximately 2.1 million shares for $9.1 million by May 15, highlighting management’s view that the stock is undervalued while raising questions about capital allocation before Phase 3.
• Apnimed has already submitted AD109 for United States approval after completing two Phase 3 trials, giving a competing oral sleep apnea therapy a potentially significant first-mover advantage.
• Eli Lilly and Company’s Zepbound has validated pharmaceutical treatment of obstructive sleep apnea in adults with obesity, but IHL-42X could seek a broader position that includes patients without obesity and those unable to tolerate positive airway pressure.
• A sustained revaluation will likely require successful recruitment, a well-tolerated optimized dose, stronger evidence of consistent patient benefit and a Phase 3 strategy that explains how IHL-42X will compete against AD109 and Zepbound.